Evidence map›Paper›PMID 39350781›Full record

ArticleWorld journal of gastroenterology2024

Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.

Sara R Lopes, Claudio Martins, Madalena Teixeira, David Tomás

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sara R LopesDepartment of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Setúbal 2910-446, Portugal.
Claudio MartinsDepartment of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Setúbal 2910-446, Portugal. cmartins1@campus.ul.pt.
Madalena TeixeiraDepartment of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Setúbal 2910-446, Portugal.
David TomásDepartment of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Setúbal 2910-446, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tofacitinib is an oral small-molecule Janus kinase (JAK) inhibitor that preferentially inhibits JAK1 and JAK3. Its efficacy in inducing and maintaining remission in ulcerative colitis (UC) as well as its safety profile has been demonstrated in multicenter, randomized, double-blind, placebo-controlled trials. Additionally, real-world studies evaluating the effectiveness and adverse effects of tofacitinib have been conducted, affirming its clinical efficacy in moderate-to-severe UC.

Indexed as

Colitis, UlcerativePiperidinesProtein Kinase InhibitorsPyrimidinesRemission InductionSeverity of Illness IndexHumansJanus Kinase 1Janus Kinase 3Janus Kinase InhibitorsPyrrolesRandomized Controlled Trials as TopicTreatment OutcomeJanus Kinase 1Janus Kinase 3Janus Kinase InhibitorsPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolestofacitinibInflammatory bowel diseaseJanus kinase inhibitorReal-world studiesTofacitinibUlcerative colitis

Identifiers

PMID39350781
PMCPMC11438653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.